TAKE®

August 11, 2026

TAKE/BSE/2026-27
The Manager
Dept. of Corporate Services-Listing
BSE Limited,
P. J. Towers, Dalal Street,
Mumbai - 400001
Script Code: 532890
Script Id: TAKE

TAKE/NSE/2026-27
The Manager-Listing
Department National Stock Exchange of India Limited
Exchange Plaza, Bandra - Kurla Complex,
Bandra (East), Mumbai - 400051
Scrip: TAKE

Reference: **Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").**

Subject: **Outcome of the Board Meeting held on Tuesday, August 11, 2026.**

Dear Sir / Madam,

In furtherance to our Intimation of Board Meeting dated August 04, 2026, we hereby inform that the meeting of Board of Directors of the Company was held today i.e. **Tuesday, August 11, 2026** at the Registered office of the company. The board has considered and approved the following business transactions in the meeting:

- The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026, along with the Limited Review Reports thereon.
- Press Release on the aforesaid financial results.

The Board Meeting commenced at 05:00 p.m. (IST) and concluded at 06:00 p.m. (IST).

You are requested to take the above cited information on your records.

Thanking You,
For TAKE Limited
(Formerly known as TAKE Solutions Limited)

TAKE LIMITED

Parmeshvar Dhangare
Chairman & Director
DIN: 11410125

TAKE®

TAKE Limited delivers strong Q1 FY27 Performance with Consolidated Revenue of ₹30.37 Cr and Net Profit of ₹ 1.06 Cr.

Strategic Entry into Biohacking, Science-Backed Nutraceuticals, and Digital Longevity Solutions.

YoY Consolidated Revenue Surges to ₹30.37 Crore	Finance Costs Drop 99.6% YoY to ₹0.07 Lakhs	Consolidated Net Profit After Tax ₹1.06 Cr

CHENNAI, August 11, 2026 — TAKE Limited, a global technology-driven healthcare company, today announced its unaudited financial results for the first quarter ended June 30, 2026 (Q1 FY 2026-27). Demonstrating significant operational momentum, the Company delivered Consolidated Revenue from Operations of ₹3,037.33 Lakhs (₹30.37 Crore) and a Consolidated Net Profit of ₹106.26 Lakhs (₹1.06 Crore), reversing a Net Loss of ₹(91.00) Lakhs in the corresponding prior-year period.

KEY FINANCIAL PERFORMANCE HIGHLIGHTS (Q1 FY 2026-27)

Consolidated Revenue & Total Income: Consolidated Revenue from Operations expanded dramatically to ₹3,037.33 Lakhs compared to Nil revenue in Q1 FY26. Total Income reached ₹3,170.11 Lakhs (₹31.70 Crore), backed by commercial scaling and execution.

Profitability: Consolidated Profit Before Tax (PBT) and Net Profit After Tax (PAT) reached ₹106.26 Lakhs, marking a complete return to profitability compared to a Net Loss of ₹(91.00) Lakhs in Q1 FY26.

Finance Costs: Finance costs plummeted by 99.62% YoY to just ₹0.07 Lakhs (down from ₹17.50 Lakhs in Q1 FY26), reflecting debt elimination, interest burden reduction, and a clean capital structure.

Earnings Per Share (EPS): Basic and Diluted EPS turned positive at ₹0.07 per share (Face Value Re. 1/-), up from negative ₹(0.06) per share in Q1 FY26.

Standalone Performance: Standalone Revenue from Operations surged to ₹1,196.90 Lakhs (vs ₹0.65 Lakhs in Q1 FY26), with Net Profit turning around to ₹96.83 Lakhs (vs a Net Loss of ₹216.45 Lakhs in Q1 FY26).

STRATEGIC VISION: DISRUPTING THE LONGEVITY & ANTI-AGEING LANDSCAPE:

Building on its restructured, lean balance sheet and deep heritage in life sciences, clinical research, and regulatory execution, TAKE Limited recently announced its strategic entry into India's rapidly accelerating Longevity, Biohacking, and Preventive Healthcare market.

TAKE LIMITED

Strategic Vectors & Market Opportunity:

Expanding Addressable Market (TAM): The global longevity market is projected to grow from USD 27.61 Billion in 2025 to USD 67.03 Billion by 2035 (9.41% CAGR). In India, the preventive healthcare market reached USD 197 Billion in 2025, with anti-aging supplements expected to expand from USD 168.6 Million in 2025 to USD 341.4 Million by 2033 (9.5% CAGR) and anti-aging services reaching USD 1.06 Billion by 2035.

Dual Business Model: TAKE Limited's strategy integrates science-backed nutraceuticals and biohacking consumer products with technology-enabled predictive digital tools to track and optimize metabolic health, sleep, cognition, and biological aging.

High-Margin, Recurring Revenue Potential: The model focuses on high repeat-purchase consumer wellness categories, generating predictable, margin-accretive revenue streams while leveraging existing clinical capabilities for rapid regulatory validation.

"Our Q1 FY27 results reflect the successful stabilization and revitalization of TAKE Limited's operational framework. With an extremely clean balance sheet, near-zero finance costs, and profitable operations, we are now executing our next growth phase. Our strategic entry into the Longevity and Anti-Ageing sector positions TAKE Limited at the intersection of life sciences, technology, and consumer wellness. By combining our regulatory and clinical domain expertise with cutting-edge biohacking and predictive digital tools, we are building a scalable, high-margin platform that addresses the multi-billion-dollar shift toward proactive health optimization." **Parmeshvar Dhangare, Director, TAKE Limited.**

About TAKE Limited:

TAKE Limited *(Formerly known as TAKE Solutions Limited)* is a global technology company delivering domain-intensive solutions and services for the life sciences and supply chain industries. With deep expertise in building scalable digital platforms and data-driven solutions, the company focuses on enabling enterprises to improve efficiency, compliance, and decision-making. Through its expanding investments in AI, analytics, and digital health technologies, TAKE Limited is positioning itself to participate in the next wave of innovation, ensuring its solutions address humancentric challenges across healthcare and other knowledge-led industries.

TAKE LIMITED

A. Raghavendra Rao & Associates.,
Chartered Accountants

Flat No. SF-2, 2nd Floor, Sampurna chambers,
No. 13, Vasavi Temple Street, V. V. Puram,
Basavanagudi, Bengaluru-560004.
Ph: 080-26625335, +9194495-34815
Email: arra.bangalore@yahoo.com

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT OF TAKE LIMITED ON THE QUARTERLY AND YEAR TO DATE UNAUDITED STANDALONE FINANCIAL RESULTS

To,

The Management

Take Limited
Regd. Off. No. B3. No.9, B Block, Alsa Arcade,3rd Floor,
2nd Avenue, Perambur Purasawalkam, Chennai,
Tamil Nadu,600102-India.

We have reviewed the accompanying **Unaudited Standalone Financial Results** of Take Limited ("the Company"), which comprise the Balance Sheet as at 30th June 2026 and year to date from 01st April 2026 to 30th June 2026, the Statement of Profit and Loss and other relevant statements for the period then ended, and a summary of significant accounting policies and other explanatory information (collectively referred to as the "Quarterly Financial Statements").

Management's Responsibility

The preparation of these Quarterly Financial Statements is the responsibility of the Company's Management, including the design, implementation, and maintenance of internal control relevant to the preparation and presentation of the financial statements statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standards 34, (Ind AS 34) "Interim Financial reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with the Regulation 33 of the listing Regulations.

Auditor's Responsibility

Our responsibility is to issue a report on these Quarterly Financial Statements based on our limited review. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.

A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

A. Raghavendra Rao & Associates
Chartered Accountants
FRN: 003324S

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Quarterly Financial Statements are not prepared, in all material respects, in accordance with the applicable accounting standards and other recognized accounting practices. Furthermore, as per the information provided by the management, nothing has come to our attention that causes us to believe that the Company has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed.
\

Restriction on Use

This report has been prepared exclusively for the internal use of the Management. Accordingly, this report should not be used, circulated, quoted, or distributed for any other purpose or to any other parties without our prior written consent.

For A. Raghavendra Rao & Associates
Chartered Accountants
FRN. 003324S

A Raghavendra Rao & Associates
Chartered Accountants
FRN : 003324S

CA G. Sathyanarayana
Partner
M No. 205603
UDIN: 26205603ENNRPT7137

Place: Bengaluru
Date: 11-08-2026

TAKE Limited
(Formerly known as TAKE Solutions Limited)
CIN: L72100TN2000PLC046338
Regd. Off. No. B3. No.9, B Block, Alsa Arcade, 3rd Floor, 2nd Avenue, Anna Nagar East, Chennai-600102, Tamil Nadu
Tel: 8108618322 E-mail: investorrelations@takelimited.com Website: www.takesolutions.com
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2026

(Rs. in Lakhs)

Sr.No.	Particulars	STANDALONE			
		QUARTER ENDED			
		3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Previous Year ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		Un-audited	Audited	Un-audited	Audited
1	**Income**				
	a) Revenue from Operations	1196.90	0.00	0.65	0.00
	b) Other Income	132.78	518.49	0.00	661.75
	Total Income	**1329.68**	**518.49**	**0.65**	**661.75**
2	**Expenses**				
	a) Cost of materials consumed	0.00	**0.00**	0.00	0.00
	b) Purchases of stock-in trade	1196.92	**0.00**	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	**0.00**	0.00	0.00
	d) Finance costs	0.07	**0.00**	14.79	29.44
	e) Employee benefits expense	7.40	**1.46**	13.58	42.14
	f) Depreciation and amortisation expense	0.02	**0.20**	0.20	0.81
	g) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	28.44	**77.64**	188.52	302.43
	Total expenses	**1232.85**	**79.31**	**217.10**	**374.82**
3	**Profit / (Loss) before exceptional items and tax (1-2)**	**96.83**	**439.18**	**-216.45**	**286.93**
4	Exceptional Items	0.00	0.00	0.00	0.00
5	**Profit/(Loss) before tax (3-4)**	**96.83**	**439.18**	**-216.45**	**286.93**
6	**Tax Expense:**				
	(a) Current Tax	0.00	0.00	0.00	0.00
	(b) Income Tax for Earlier Period	0.00	0.00	0.00	16.02
7	**Total Tax Expenses**	**0.00**	**0.00**	0.00	**16.02**
8	**Profit/ (Loss) for a period from continuing operations (5-7)**	**96.83**	**439.18**	**-216.45**	**270.91**
9	Profit/(Loss) for a period from dis-continuing operations	0.00	0.00	0.00	1.00
10	Tax Expenses of Discontinued Operations	0.00	0.00	0.00	0.00
11	**Profit/ (Loss) for a period from dis-continuing operations (after tax) (9-10)**	**0.00**	**0.00**	**0.00**	**1.00**
12	**Net Profit/(Loss) (8+11)**	**96.83**	**439.18**	**-216.45**	**271.91**

TAKE LIMITED

13	**Other Comprehensive income / (Loss)**				
	A) (i) Amount of items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	B) (i) Amount of items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
14	**Total Comprehensive income for the period (comprising profit/loss) and other comprehensive income for the period (12+13)**	**96.83**	**439.18**	**-216.45**	**271.91**
	Paid-up Equity Share Capital (Face Value of Re. 1/- each)	1479.34	1479.34	1479.34	1479.34
15	**Earnings Per Share (For continuing operations)**				
	a) Basic	**0.07**	**0.30**	**-0.15**	**0.18**
	b) Diluted	**0.07**	**0.30**	**-0.15**	**0.18**

For TAKE Limited

(Formerly known as TAKE Solutions Limited)

TAKE LIMITED

Parmeshvar Dhangare
Chairman & Director
DIN: 11410125

Date: August 11, 2026
Place: Chennai

A. Raghavendra Rao & Associates.,
Chartered Accountants
INDIA

Flat No. SF-2, 2nd Floor, Sampurna Chambers,
No. 13, Vasavi Temple Street, V. V. Puram,
Basavanagudi, Bengaluru-560004.
Ph: 080-26625335, +9194495-34815
Email: arra.bangalore@yahoo.com

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT OF TAKE LIMITED ON THE QUARTERLY AND YEAR TO DATE UNAUDITED CONSOLIDATED FINANCIAL RESULTS

To,
The Management
Take Limited
Regd. Off. No. B3. No.9, B Block, Alsa Arcade,3rd Floor,
2nd Avenue, Perambur Purasawalkam, Chennai,
Tamil Nadu,600102-India.

We have reviewed the accompanying **Unaudited Consolidated Financial Results** of **TAKE LIMITED** ("the Holding Company"), and its Subsidiaries ("the Holding and its Subsidiary referred to as "the Group") which comprise the Balance Sheet as at 30th June and year to date from 01st April, 2026 to 30th June, 2026, the Statement of Profit and Loss and other relevant statements for the period then ended, and a summary of significant accounting policies and other explanatory information (collectively referred to as the "Quarterly Financial Statements").

This Statement includes the results of the Subsidiary Take Ventures Private Limited.

Management's Responsibility

The preparation of these Quarterly Financial Statements is the responsibility of the Holding Company's Management, including the design, implementation, and maintenance of internal control relevant to the preparation and presentation of the financial statements in accordance with the recognition and measurement principles laid down in Indian Accounting Standards 34, (Ind AS 34) "Interim Financial reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with the Regulation 33 of the listing Regulations.

Auditor's Responsibility

Our responsibility is to issue a report on these Quarterly Financial Statements based on our limited review. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.

A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all

Raghavendra Rao & Associates Chartered Accountants FRN: 003324S significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Quarterly Financial Statements are not prepared, in all material respects, in accordance with the applicable accounting standards and other recognized accounting practices. Furthermore, as per the information provided by the management, nothing has come to our attention that causes us to believe that the Company has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed.

Restriction on Use

This report has been prepared exclusively for the internal use of the Management. Accordingly, this report should not be used, circulated, quoted, or distributed for any other purpose or to any other parties without our prior written consent.

For A. Raghavendra Rao & Associates
Chartered Accountants
FRN. 003324S

A Raghavendra Rao & Associates
Chartered Accountants
FRN : 003324S

CA G. Sathyanarayana
Partner
M No. 205603
UDIN: 26205603CXVXZC6962

Place: Bangalore
Date: 11-08-2026

TAKE Limited (Formerly known as TAKE Solutions Limited)						
CIN: L72100TN2000PLC046338						
Regd. Off. No. B3. No.9, B Block, Alsa Arcade, 3rd Floor, 2nd Avenue, Anna Nagar East, Chennai-600102, Tamil Nadu						
Tel: 8108618322 E-mail: investorrelations@takelimited.com Website: www.takesolutions.com						
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2026						
					(Rs. in Lakhs)	

Sr. No.	Particulars	CONSOLIDATED			
		QUARTER ENDED			
		3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Previous Year ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		Un-audited	Audited	Un-audited	Audited
1	**Income**				
	a) Revenue from Operations	3037.33	5418.53	0.00	5418.53
	b) Other Income	132.78	518.49	4.10	668.73
	Total Income	**3170.11**	**5937.02**	**4.10**	**6087.26**
2	**Expenses**				
	a) Cost of materials consumed	0.00	0.00	0.00	0.00
	b) Purchases of stock-in trade	3026.79	5419.95	0.00	5419.95
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00
	d) Finance costs	0.07	0.00	17.50	34.89
	e) Employee benefits expense	7.40	1.46	13.60	42.20
	f) Depreciation and amortisation expense	0.02	0.20	0.20	0.81
	g) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	29.58	79.42	31.30	147.81
	Total expenses	**3063.85**	**5501.03**	**62.60**	**5645.66**
3	**Profit / (Loss) before exceptional items and tax (1-2)**	**106.26**	**435.99**	**-58.50**	**441.60**
4	Exceptional Items	0.00	0.00	0.00	0.00
5	**Profit/(Loss) before tax (3-4)**	**106.26**	**435.99**	**-58.50**	**441.60**
6	**Tax Expense:**				
	(a) Current Tax	0.00	0.00	0.00	0.00
	(b) Income Tax for Earlier Period	0.00	0.00	0.00	16.00
7	**Total Tax Expenses**	**0.00**	**0.00**	**0.00**	**16.00**
8	**Profit/(Loss) for a period from continuing operations (5-7)**	**106.26**	**435.99**	**-58.50**	**425.60**
9	Profit/(Loss) for a period from dis-continuing operations	0.00	0.00	-32.50	659.30
10	Tax Expenses of discontinued operations	0.00	0.00	0.00	0.00
11	**Profit/ (Loss) for a period from dis-continuing operations (after tax) (9-10)**	**0.00**	**0.00**	**-32.50**	**659.30**
12	**Net Profit/(Loss) (8+11)**	**106.26**	**435.99**	**-91.00**	**1084.90**

TAKE LIMITED

13	**Other Comprehensive Income/ (Loss)**				
	A) (i) Amount of items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	B) (i) Amount of items that will be reclassified to profit or loss	0.00	0.00	-1.70	-1.70
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
14	**Total Comprehensive income for the period (comprising profit/loss) and other comprehensive income for the period**	**106.26**	**435.99**	**-92.70**	**1083.20**
	Paid-up Equity Share Capital (Face Value of Re. 1/- each)	1479.34	1479.34	1479.34	1479.34
15	**Earnings Per Share (For continuing operations)**				
	a) Basic	**0.07**	**0.29**	**-0.06**	**0.73**
	b) Diluted	**0.07**	**0.29**	**-0.06**	**0.73**

For TAKE Limited

(Formerly known as TAKE Solutions Limited)

TAKE LIMITED

Parmeshvar Dhangare
Chairman & Director
DIN: 11410125

Date: August 11, 2026
Place: Chennai

Notes:

1. The Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026 were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 11, 2026.

2. The Statutory Auditors of the Company have carried out a Limited Review of the financial results for the quarter ended June 30, 2026 in compliance with terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3. The statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013, and other recognised accounting practices and policies to the extent applicable.

4. Previous period figures have been regrouped and reclassified wherever necessary.

5. As the Company's business activity falls within a single primary business segment, the disclosure requirements under Ind AS 108 'Operating Segments' are not applicable.

6. The name of the Company has been changed from "**TAKE Solutions Limited**" to "**TAKE Limited**" with effect from June 25, 2026, pursuant to the Certificate of Incorporation issued by the Ministry of Corporate Affairs.

For TAKE Limited
(Formerly known as TAKE Solutions Limited)

TAKE LIMITED

Parmeshvar Dhangar
Chairman & Director
DIN: 11410125

Date: August 11, 2026
Place: Chennai